Description
Wolverine Stack: BPC-157 + TB-500 Blend | 10MG
BioChain USA · Research use only
Overview
What Is the BPC-157 + TB-500 Research Blend?
This product contains two distinct synthetic peptides combined in a single lyophilized preparation: BPC-157 (Body Protection Compound 157, 10 mg) and TB-500 (Thymosin Beta-4 synthetic, 10 mg). Each compound has an independent mechanism and its own body of published research literature. This blend is designed for research contexts where investigators study the effects of co-administering these two peptides in experimental models.
BPC-157 (also referenced in the literature as PL-14736) is a synthetic 15-amino acid pentadecapeptide derived from a partial sequence identified within human gastric juice protein. It is studied in published literature primarily in the context of nitric oxide pathway modulation, angiogenic signaling, and interaction with growth hormone receptor systems in experimental models. TB-500 is a synthetic 43-amino acid peptide corresponding to the amino acid sequence of thymosin beta-4 (Tβ4), an endogenous G-actin sequestering protein.
In research literature, TB-500 is examined in relation to actin cytoskeletal dynamics, cell migration mechanisms, and angiogenic signaling pathways.
Education
Wolverine Stack (BPC-157 + TB-500) in Plain Language
A non-technical overview of what this two-peptide blend is, what researchers have studied each component for, what early evidence suggests, and what cannot be claimed about it. For research and educational purposes only.
At a glance
The Wolverine Stack combines BPC-157 and TB-500, two of the most-studied research peptides in tissue regeneration. BPC-157 is studied for supporting healthy blood-vessel growth and protecting tissue from injury, and TB-500 is studied for helping cells move into damaged areas and calming inflammation.
Scientists study the pair together in laboratory models because they target different parts of the repair process, blood supply and cellular movement, and the idea is that combining them may work better than either one alone. The blend sold here is a research chemical preparation, not a pharmaceutical or therapeutic product, and is not for human or animal use.
What it is
The Wolverine Stack is a research preparation combining two peptides that have been studied independently in published tissue-repair literature:
- BPC-157. A synthetic 15-amino-acid peptide (Body Protection Compound 157, also known in the clinical-trial literature as PL-14736) based on a partial sequence of a larger protein originally identified in human gastric juice. It is studied in laboratory and animal research related to tissue-repair signaling, gastrointestinal lining biology, tendon and ligament injury models, and the nitric-oxide and angiogenesis pathways.
- TB-500. A synthetic 43-amino-acid peptide identical in sequence to thymosin beta-4 (Tβ4), an actin-binding protein found inside most mammalian cells. It is studied in laboratory and animal research related to cell migration, wound-healing models, blood-vessel formation (angiogenesis), and cardiac tissue repair models.
The two peptides are commonly studied together in published preclinical literature because their mechanistic frameworks (BPC-157’s reported effects on nitric-oxide / angiogenic pathways; TB-500’s effects on actin-cytoskeletal dynamics and cell migration) are non-overlapping but converge on shared research endpoints in tissue-repair model systems.
Research areas being investigated
- Tissue-repair research: Studied in animal models of skin wounds, tendon detachment, ligament transection, ischemia/reperfusion injury, and intestinal anastomosis (BPC-157), and in animal models of dermal, corneal, and cardiac wound repair (TB-500).
- Cell-migration research: TB-500 is studied for actin-binding effects on cell migration in scratch assays and capillary-tube formation in Matrigel.
- Vascular / angiogenesis research: Both peptides are examined for effects on endothelial cell behavior and new-blood-vessel-formation endpoints.
- Gastrointestinal research: BPC-157 is studied in stomach ulcer, colitis, and gut-barrier injury models in rodents.
- Cardiac research: TB-500 / Tβ4 is studied in animal models of myocardial infarction for effects on heart-muscle cell survival and post-injury tissue remodeling.
- Inflammation research: Both peptides are studied in cell and animal models for effects on pro-inflammatory cytokine expression (TNF-α, IL-6, IL-1β).
What the research suggests so far
Animal / preclinical findings. Most published evidence on both peptides comes from rodent (mostly rat) studies. Researchers have reported observations consistent with faster healing in models of skin wounds, gastric ulcers, colitis, tendon detachment, and ischemia/reperfusion injury (BPC-157), and consistent with faster cellular migration, more capillary-tube formation, and protective effects in animal myocardial-infarction models (TB-500). These findings do not, on their own, demonstrate the same effects in humans, and combined-blend research is sparser than research on each peptide individually. Cell / lab findings. Cell-culture work has characterized BPC-157’s effects on endothelial nitric oxide synthase (eNOS) activity and VEGFR2 expression; and Tβ4’s 1:1 binding to monomeric G-actin and its effects on the G-actin / F-actin equilibrium underlying cell migration. These mechanistic findings are several steps removed from clinical outcomes.
Human findings. Human evidence for both peptides is limited. The most cited human work for BPC-157 is an early-phase clinical program under the development name PL-14736 (Pliva, Croatia) for inflammatory bowel disease. For TB-500 / Tβ4, the most cited human work involves topical and ophthalmic Tβ4 formulations (e.g., RGN-259) studied in early-phase trials. There are no large, published Phase III randomized controlled trials demonstrating efficacy for any condition. Neither BPC-157 nor TB-500 is approved by the FDA, EMA, or other major regulators for any use.
Limitations of the evidence. Most of the literature for both peptides is preclinical and traceable to a relatively small number of research groups. Long-term human safety data, large-scale efficacy trials, and standardized human dosing studies are lacking. Combined-blend research (versus each peptide individually) is comparatively limited, so most claims about “synergy” between the two are extrapolation rather than strong empirical support. Reviewers in the recent peer-reviewed literature have specifically called out the need for additional rigorous human studies before any therapeutic conclusions can be drawn.
Research relevance
The Wolverine Stack is most often discussed in research involving tissue-repair signaling, gastrointestinal mucosal biology, tendon and ligament injury models (BPC-157 lineage), actin cytoskeletal dynamics, cell migration, wound-healing models, and cardiac repair (TB-500 lineage). Most published findings are preclinical, so it should not be presented as a proven treatment for any condition.
Its scientific interest lies in its potential use as a research tool for studying tissue-repair signaling in the laboratory.
What cannot be claimed about the Wolverine Stack
- It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
- It cannot be claimed to repair tendons, ligaments, joints, muscles, hearts, or nerves in humans.
- It cannot be claimed to treat ulcers, inflammatory bowel disease, leaky gut, or any digestive condition.
- It cannot be claimed to reduce pain, accelerate recovery from surgery or sports injury, or improve athletic performance.
- It cannot be claimed to be safe or effective for human or veterinary use.
- It cannot be claimed to be approved by the FDA or any other regulatory authority.
Summary
The Wolverine Stack is a research preparation combining BPC-157 (a synthetic 15-amino-acid peptide from human gastric juice protein) and TB-500 (a synthetic 43-amino-acid peptide identical to thymosin beta-4). It is studied in laboratory and animal research on tissue-repair signaling, gut and tendon injury models, actin cytoskeletal dynamics, cell migration, blood-vessel formation, and cardiac repair models. Published evidence comes mainly from rodent and cell-culture experiments; human evidence for either peptide is limited to small early-phase studies.
Neither peptide is approved by the FDA or any other regulator. BioChain USA’s preparation is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.
Short version
The Wolverine Stack combines BPC-157 and TB-500 (synthetic thymosin beta-4). Both are most often studied in preclinical tissue-repair research. Neither is approved by the FDA. Sold for research and laboratory use only.
Source notes
- Sikiric P. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des, 2011, review article. (PubMed PMID: 21548867.)
- Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res, 2006, animal study. (PubMed PMID: 16583442.)
- Deek SA, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. 2024, peer-reviewed narrative review. (PMC12446177.)
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 2005, review article.
- Bock-Marquette I, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004, animal study.
- Sosne G, et al. Thymosin β4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial. J Ocul Pharmacol Ther, 2015, small early-phase human study (RGN-259).
Source types: entries 1, 3, 4 are review articles; entries 2, 5 are animal / preclinical studies; entry 6 is a small early-phase human ophthalmology study of an ophthalmic Tβ4 formulation.
SEO meta description
Wolverine Stack (BPC-157 + TB-500, research-grade) combines two peptides studied in preclinical research on tissue repair, vascular biology, and cell migration. Research-use only. Reminder. BioChain USA sells the Wolverine Stack strictly as a research-use-only chemical for qualified laboratory and educational use.
Neither BPC-157 nor TB-500 is FDA-approved, and this product is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.
Chemistry
Chemical Reference Data
BPC-157 (Body Protection Compound 157)
| Molecular Formula | C62H98N16O22 |
|---|---|
| Molecular Weight | ~1,419.6 g/mol |
| Peptide Length | 15 amino acids |
| Structural Classification | Synthetic pentadecapeptide derived from human gastric protein sequence |
| CAS Number | 137525-51-0 |
TB-500 (Thymosin Beta-4 Synthetic)
| Molecular Formula | C212H350N56O78S |
|---|---|
| Molecular Weight | ~4,963.5 g/mol |
| Peptide Length | 43 amino acids |
| Structural Classification | Synthetic linear polypeptide corresponding to thymosin beta-4 (Tβ4) sequence |
| CAS Number | 77591-33-4 |
Engineering
Structural Design and Engineering
BPC-157 is a synthetic peptide derived from a partial sequence of human Body Protection Compound, a protein identified in human gastric juice. The 15-amino acid sequence is described in published literature as exhibiting relative resistance to enzymatic degradation compared to many short-chain peptides, a property discussed in the research literature as attributable to its specific amino acid composition and sequence architecture. BPC-157 is not acylated or lipidated in standard formulation.
TB-500 is a synthetic 43-amino acid peptide with full sequence correspondence to thymosin beta-4 (Tβ4), an endogenous intracellular protein. Published research describes Tβ4 as the primary G-actin sequestering peptide in mammalian cells, it binds monomeric (globular) actin and modulates the equilibrium between G-actin and F-actin (filamentous, polymerized) forms. This actin-binding function is cited in the research literature as the structural basis for downstream effects observed in cell migration, angiogenesis, and cytoskeletal dynamics research models.
TB-500 is not acylated or lipidated in standard formulation. BioChain USA does not make medical claims. Research context does not equal clinical outcome data.
Applications
Research Applications
This peptide blend is used as a research tool to investigate:
- BPC-157, Nitric oxide pathway modulation in vascular and mucosal biology research models
- BPC-157, Angiogenic signaling including VEGF-related pathway investigation in in vitro and preclinical systems
- BPC-157, Gut and mucosal barrier biology, gastrointestinal epithelial and systemic signaling contexts in preclinical research
- BPC-157, Growth hormone receptor interactions as described in published pharmacology literature
- TB-500, Actin dynamics and cytoskeletal remodeling, G-actin vs. F-actin equilibrium and downstream effects on cell structure and motility
- TB-500, Cell migration research in wound healing and tissue remodeling model systems
- TB-500, Angiogenesis-related signaling including endothelial cell behavior and vessel formation contexts
- Combined co-administration research design, studying the effects of BPC-157 and TB-500 administered together in preclinical model systems, a documented research design in published peptide literature
Specific applications depend on the researcher’s study design, cell model, and assay framework.
Literature
Key Research Themes in the Literature
1. BPC-157: Nitric Oxide Signaling and Angiogenesis
BPC-157 is examined in published literature in relation to nitric oxide (NO) pathway regulation. Research themes include interactions with endothelial nitric oxide synthase (eNOS) signaling and downstream vascular biology effects in experimental systems. In angiogenesis-related research, BPC-157 has been discussed in the context of VEGF (vascular endothelial growth factor) pathway modulation, endothelial cell behavior, and vessel formation responses in in vitro assay frameworks.
Additional published research themes include interaction with growth hormone receptor systems, some literature describes BPC-157 as influencing growth hormone receptor expression or sensitization in specific preclinical model contexts. BPC-157 has also been examined in gastrointestinal research for its proposed role in mucosal barrier biology and gut epithelial signaling pathways. Human clinical evidence for BPC-157 is limited.
Published findings are primarily from in vitro and animal model research. BioChain USA does not represent preclinical findings as consumer outcomes.
2. TB-500 (Tβ4): Actin Dynamics and Cell Migration
Thymosin beta-4 is one of the most abundant intracellular peptides in mammalian cells and is described in published biochemistry literature as the primary G-actin sequestering protein. TB-500 research examines:
- Actin monomer sequestration, Tβ4 binds G-actin at approximately a 1:1 molar ratio in published biochemical studies, directly modulating the available pool of monomeric actin for filament assembly
- Cell migration and motility, changes in actin polymerization dynamics are discussed in the literature as influencing cell migration behavior in wound healing and tissue remodeling model systems
- Cytoskeletal remodeling, downstream structural changes in F-actin organization examined in cell biology and tissue repair research contexts
- Anti-inflammatory signaling contexts, Tβ4 has been examined in published literature in relation to inflammatory marker expression in preclinical models
3. Shared Research Theme: Angiogenesis and Vascular Biology
Both BPC-157 and TB-500 (Tβ4) appear independently in angiogenesis-related research literature. Published research on Tβ4 includes investigation of its role in vessel formation, it has been studied in cardiac and vascular research contexts, including work examining VEGF pathway involvement and endothelial cell migration.
BPC-157 appears in overlapping angiogenesis and vascular biology research themes through the NO and VEGF pathway contexts described above. This mechanistic overlap in vascular and tissue remodeling biology is commonly cited in published research as a rationale for studying these two peptides together in preclinical co-administration designs.
4. Co-Administration Research Design Context
BPC-157 and TB-500 are frequently discussed together in preclinical research literature as complementary compounds based on their respective, and partially overlapping, mechanisms. Published study designs using both peptides in combination are documented in animal model literature examining tissue repair, regeneration, and recovery-related endpoints. Researchers use co-administration models to examine potential additive or synergistic effects across the respective signaling pathways of each compound.
BioChain USA does not represent preclinical co-administration findings as consumer outcomes or therapeutic claims. These are research literature contexts only.
Documentation
Certificate of Analysis (COA)
- COA provided where available for the specific batch shipped.
- The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
- COA information is batch-specific and is not interchangeable between lots. For blend products, COA documentation reflects testing of the combined preparation as shipped.
Handling
Storage and Handling
General peptide handling guidance for research use:
- Store in a cool, dry, dark environment.
- For extended storage, follow standard peptide handling protocols: cold storage with protection from light and moisture.
- Avoid repeated open-close cycles that introduce humidity to the lyophilized material.
- If preparing solutions for laboratory use, standard guidance recommends avoiding long-term storage in reconstituted form, aliquot as appropriate for the experimental design.
BioChain USA does not provide instructions for human or animal administration.
FAQ
Frequently Asked Questions
Is this product for human use?
No. This peptide blend is not approved or intended for human or veterinary use. It is sold exclusively for in vitro research, laboratory, and analytical purposes. It is not a drug, supplement, or therapeutic product of any kind.
What are BPC-157 and TB-500 used for in research?
BPC-157 is studied for nitric oxide pathway modulation, angiogenic signaling, gut and mucosal biology, and growth hormone receptor interactions in preclinical and in vitro model systems. TB-500 (Thymosin Beta-4 synthetic) is studied for actin cytoskeletal dynamics, cell migration, cytoskeletal remodeling, and angiogenesis-related signaling.
Co-administration research designs examine the combined effects of both peptides in preclinical models. Specific applications depend on the researcher’s study design and objectives.
Do you provide dosing instructions or administration protocols?
No. BioChain USA does not provide dosing guidance, administration instructions, or protocols for human or animal use. Researchers are responsible for designing in vitro study protocols appropriate to their applications and institutional requirements.
Do you provide a Certificate of Analysis (COA)?
Yes, where available. COAs are batch-specific documents reflecting the analytical testing and purity data for that particular lot. The COA included with your order is the authoritative reference for that batch. Availability may vary by lot.
Compliance
Compliance and Disclaimers
- Sold for research, laboratory, or analytical purposes only.
- Not intended to diagnose, treat, cure, or prevent any disease or condition.
- Not for human or animal consumption.
- Purchaser assumes full responsibility for compliance with all applicable local, state, and federal regulations governing the purchase and use of research compounds.
References & additional Wolverine resources
Wolverine Overview at BioChain USA
This Wolverine product page lists the 10 mg lyophilized vial of the BioChain USA research-grade Wolverine compound.
Every Wolverine lot is independently third-party tested, with a COA available per batch.
Wolverine is supplied strictly for in vitro research use and is not approved for human or animal consumption.
Wolverine Product Imagery
Related BioChain Research Peptides
Wolverine is part of a broader catalog of research-grade peptides at BioChain USA. Each related product is third-party tested.
- BPC-157 research-grade peptide
- TB-500 research-grade peptide
- KLOW research-grade peptide
- GLOW research-grade peptide
External Peer-Reviewed Research Literature
Investigators studying the Wolverine compound class may consult external research databases for published literature.
- PubMed: Wolverine published research literature
- NCBI PMC: Wolverine open access articles
- PubMed: peptide research literature
Wolverine FAQ
What is Wolverine? Wolverine is a research-grade compound supplied by BioChain USA as a lyophilized vial for in vitro laboratory research only.
What vial size does BioChain USA offer? This product page lists the 10 mg vial size.
Is Wolverine tested? Yes. Every Wolverine lot is independently third-party tested and ships with a COA reference when available.
Can Wolverine be used on humans or animals? No. Wolverine is supplied strictly for in vitro research use. It is not approved for human or animal consumption.
How does Wolverine ship? BioChain USA ships Wolverine as a lyophilized powder in a sealed research vial.
Where can researchers find Wolverine published literature? PubMed and NCBI PMC list peer-reviewed studies on the Wolverine compound class.
